Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

(This section is what permits Hims & Hers to produce otherwise patent-protected GLP-1 drugs while the supply of such drugs is in deficit.) As regards semaglutide, FDA says compounders such as Hims ...

Hims & Hers (NYSE: HIMS) stock is down 50% from its peak earlier this year, but the drop in shares hasn't been driven by deteriorating operations. In fact, the company is growing as fast as ever.

Hims & Hers Health is now reasonably valued after ... The recent drop now makes the stock reasonably valued, at least if it can maintain high free cash flow growth for a while, which seems possible.

The Dow Jones showed a 726-point drop at one point during Leavitt’s press briefing on Tuesday, which followed the massive ...

The stock is up more than 40% since the beginning of the year, peaking in mid-February after Hims & Hers ran a controversial commercial about its weight-loss platform during the Super Bowl and ...

Nancy Pelosi's wealth has significantly declined due to a rough year for her investment portfolio. Her net worth has dropped ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...